Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
University of Nottingham - School of Medicine - Radiological Sciences, Nottingham, Nottinghamshire, United Kingdom
University Hospital of Toulouse, Toulouse, France
Birmingham Clinical Trials Unit, Birmingham, West Midlands, United Kingdom
Albany Medical Center, Albany, New York, United States
Aslı Demir, Ankara, Turkey
Turkey Yuksek Ihtisas Education and Research Hospital, Ankara, Turkey
Department of Anesthesiology and Pain Medicine, Yeungnam University hospital, Daegu, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.